Metformin inhibits the senescence‐associated secretory phenotype by interfering with <scp>IKK</scp>/<scp>NF</scp>‐κ<scp>B</scp> activation

Olga Moiseeva(Zero to Three), Xavier Deschênes‐Simard(Zero to Three), Emmanuelle St‐Germain(Université de Montréal), Sebastian Igelmann(Université de Montréal), Geneviève Huot(Université de Montréal), Alexandra Elena Cadar(Université de Montréal), Véronique Bourdeau(Université de Montréal), Michaël Pollak(Jewish General Hospital), Gerardo Ferbeyre(Université de Montréal)
Aging Cell
March 23, 2013
Cited by 627Open Access
Full Text

Abstract

We show that the antidiabetic drug metformin inhibits the expression of genes coding for multiple inflammatory cytokines seen during cellular senescence. Conditioned medium (CM) from senescent cells stimulates the growth of prostate cancer cells but treatment of senescent cells with metformin inhibited this effect. Bioinformatic analysis of genes downregulated by metformin suggests that the drug blocks the activity of the transcription factor NF-κB. In agreement, metformin prevented the translocation of NF-κB to the nucleus and inhibited the phosphorylation of IκB and IKKα/β, events required for activation of the NF-κB pathway. These effects were not dependent on AMPK activation or on the context of cellular senescence, as metformin inhibited the NF-κB pathway stimulated by lipopolysaccharide (LPS) in ampk null fibroblasts and in macrophages. Taken together, our results provide a novel mechanism for the antiaging and antineoplastic effects of metformin reported in animal models and in diabetic patients taking this drug.


Related Papers

No related papers found

Powered by citation graph analysis